Ensign Peak Advisors, Inc Catalyst Pharmaceuticals, Inc. Transaction History
Ensign Peak Advisors, Inc
- $56.1 Billion
- Q3 2024
A detailed history of Ensign Peak Advisors, Inc transactions in Catalyst Pharmaceuticals, Inc. stock. As of the latest transaction made, Ensign Peak Advisors, Inc holds 48,160 shares of CPRX stock, worth $1.1 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
48,160
Previous 48,160
-0.0%
Holding current value
$1.1 Million
Previous $745,000
28.46%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding CPRX
# of Institutions
342Shares Held
98.1MCall Options Held
19.1KPut Options Held
51.1K-
Black Rock Inc. New York, NY18.7MShares$425 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.43MShares$192 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY6.23MShares$142 Million2.3% of portfolio
-
State Street Corp Boston, MA5.69MShares$129 Million0.0% of portfolio
-
Dimensional Fund Advisors LP Austin, TX3.02MShares$68.7 Million0.01% of portfolio
About CATALYST PHARMACEUTICALS, INC.
- Ticker CPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 102,820,000
- Market Cap $2.34B
- Description
- Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthe...